HQY:NASDAQ
Healthequity Inc
$92.61
arrow_downward
-0.47%(-0.44) 1D
$92.61
0.00% (0.00)
bedtimeAfter hours
Closed: Oct 9, 4:00:01 PM GMT-4 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for HQY...
Open
$92.98
High
$93.96
Low
$92.02
Mkt. cap
7.66B
Avg. vol.
998.94K
Volume
555.91K
P/E ratio
33.46
52-wk high
$107.62
52-wk low
$72.76
EPS
$2.77
Beta
0.24
Shares outstanding
82.72M
No. of employees
3K
Open
$92.98
High
$93.96
Low
$92.02
Mkt. cap
7.66B
Avg. vol.
998.94K
Volume
555.91K
P/E ratio
33.46
52-wk high
$107.62
52-wk low
$72.76
EPS
$2.77
Beta
0.24
Shares outstanding
82.72M
No. of employees
3K
News stories
From web sources and news partners
TipRanks
·
6 hours ago
HealthEquity Announces Chief Commercial Officer Leadership Change
Stock Titan
·
8 hours ago
One investment adviser reports a passive stake of 7.01 million shares in HealthEquity (HQY).
Stock Titan
·
1 day ago
Former executive Fiore holds 50,212 direct shares in HealthEquity (HQY) after disposing of 2,032 shares.
Investing.com India
·
1 day ago
Form 4 Healthequity Inc For: 8 October By Investing.com
Profile
HealthEquity, Inc. is an American financial technology and business services company that is designated as a non-bank health savings trustee by the IRS. This designation allows HealthEquity to be the custodian of health savings accounts regardless of which financial institution the funds are deposited with.
As of July 31, 2022, HealthEquity managed 7.5 million HSA accounts, plus 7 million other consumer-directed benefits for total accounts of 14.5 million. Total HSA assets as of July 31, 2022 were $20.5 billion, including $13.1 billion of HSA cash and $7.4 billion of HSA investments. Wikipedia
About Healthequity Inc
CEOJon Kessler
Employees2.81K
FoundedJan 1, 2002
HeadquartersDraper, Utah, United States
SectorHealth care provider
Websitehealthequity.com
Analyst ratings
Based on 9 analysts giving stock ratings to HQY in the past 3 months
Strong buy
Buy
9
Hold
0
Sell
0
12-month forecast
Based on 9 Wall Street analysts offering 12 month price targets for HQY in the last 3 months.
Highest
Current $92.61
$142.00 (+53.33%)
Average
$118.89 (+28.38%)
Lowest
$105.00 (+13.38%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Ryan Halsted RBC Capital | Buy | Maintained | $108.00 | +16.6% | 10/06/2026 |
Stan Berenshteyn Wells Fargo | Buy | Reiterated | $125.00 | +35% | 09/29/2026 |
Peter Warendorf Barclays | Buy | Reiterated | $115.00 | +24.2% | 09/18/2026 |
George Hill Deutsche Bank | Buy | Reiterated | $142.00 | +53.3% | 08/31/2026 |
Alexander Paris Barrington | Buy | Reiterated | $110.00 | +18.8% | 08/28/2026 |
Sean Dodge BMO Capital | Buy | Maintained | $105.00 | +13.4% | 08/28/2026 |
David Larsen BTIG | Buy | Maintained | $115.00 | +24.2% | 08/28/2026 |
Allen Lutz Bank of America Securities | Buy | Reiterated | $125.00 | +35% | 08/28/2026 |
Scott Schoenhaus KeyBanc | Buy | Maintained | $125.00 | +35% | 08/18/2026 |
Alexei Gogolev J.P. Morgan | Buy | Reiterated | $123.00 | +32.8% | 06/25/2026 |
Constantine Davides Citizens JMP | Buy | Maintained | $111.00 | +19.9% | 06/01/2026 |
David Roman Goldman Sachs | Sell | Maintained | $88.00 | -5% | 05/29/2026 |
Daniel Perlin RBC Capital | Buy | Reiterated | $100.00 | +8% | 03/17/2026 |
Brian Tanquilut Jefferies | Buy | Maintained | $108.00 | +16.6% | 02/19/2026 |
Gregory Peters Raymond James | Buy | Reiterated | $100.00 | +8% | 02/17/2026 |
Last report
Aug 27, 2026
Fiscal period
Q2 2027
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
$1.24 / $1.19
+3.91%beat
arrow_upward
Revenue / Est. (USD)
350.73M / 349.23M
+0.43%beat
arrow_upward
Fiscal Q2 2027 earnings call
youtube_liveWaiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Oct 2025 | Jan 2026 | Apr 2026 | Jul 2026 |
|---|---|---|---|---|
Revenue | 322.16M | 334.59M | 354.64M | 350.73M |
Cost of goods sold | 94.10M | 106.44M | 98.33M | 92.78M |
Cost of revenue | 94.10M | 106.44M | 98.33M | 92.78M |
Research and development expenses | 65.92M | 70.35M | 67.77M | 73.92M |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 55.29M | 58.45M | 57.96M | 58.08M |
Operating expense | 148.21M | 155.75M | 152.25M | 158.29M |
Total operating expenses | 242.31M | 262.19M | 250.58M | 251.07M |
Operating income | 79.85M | 72.40M | 104.07M | 99.66M |
Other non operating income | 22.00K | 329.00K | 161.00K | 20.00K |
EBT including unusual items | 67.53M | 60.90M | 92.41M | 87.86M |
EBT excluding unusual items | 68.69M | 62.22M | 93.53M | 88.84M |
Income tax expense | 15.84M | 11.16M | 23.00M | 22.22M |
Effective tax rate | 23.46% | 18.32% | 24.88% | 25.29% |
Other operating expenses | - | - | - | - |
Net income | 51.69M | 49.74M | 69.42M | 65.64M |
Net profit margin | 16.05% | 14.87% | 19.57% | 18.72% |
Earnings per share | 1.01 | 0.95 | 1.24 | 1.24 |
Interest and investment income | 2.86M | 2.77M | 1.89M | 1.76M |
Interest expense | -14.05M | -13.27M | -12.59M | -12.60M |
Net interest expenses | -11.18M | -10.50M | -10.70M | -10.84M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 118.63M | 111.08M | 142.28M | 141.62M |
Gain or loss from assets sale | - | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1